反応式
[Cl:1][C:2]1[C:3]2[C:10](I)=[CH:9][N:8]([C@H:12]3[CH2:17][CH2:16][C@H:15]([N:18]4[CH2:23][CH2:22][N:21]([CH3:24])[CH2:20][CH2:19]4)[CH2:14][CH2:13]3)[C:4]=2[N:5]=[CH:6][N:7]=1.[F:25][C:26]1[CH:27]=[C:28](B2OC(C)(C)C(C)(C)O2)[CH:29]=[CH:30][C:31]=1[O:32][C:33]1[CH:38]=[CH:37][CH:36]=[CH:35][CH:34]=1.ClC1C2C(C3C=CC(OC4C=CC=CC=4)=C(C=3)C#N)=CN([C@H]3CC[C@H](N4CCN(C)CC4)CC3)C=2N=CN=1.CO[C@@H]1[C@@H](C(OC)=O)[C@@H]2[C@@H](CN3[C@H](C2)C2NC4C=C(OC)C=CC=4C=2CC3)C[C@H]1OC(C1C=C(OC)C(OC)=C(OC)C=1)=O>C(#N)C>[C:33]1([O:32][C:31]2[CH:30]=[CH:29][C:28]([C:10]3[C:3]4[C:2]([Cl:1])=[N:7][CH:6]=[N:5][C:4]=4[N:8]([C@H:12]4[CH2:17][CH2:16][C@H:15]([N:18]5[CH2:23][CH2:22][N:21]([CH3:24])[CH2:20][CH2:19]5)[CH2:14][CH2:13]4)[CH:9]=3)=[CH:27][C:26]=2[F:25])[CH:34]=[CH:35][CH:36]=[CH:37][CH:38]=1参加物
6
実験手順
The title compound was prepared in an 85% yield from trans-4-chloro-5-iodo-7-[4-(4-methylpiperazino)cyclohexyl]-7H-pyrrolo[2,3-d]pyrimidine and 2-(3-fluoro-4-phenoxyphenyl)-4,4,5,5-tetrametyl-1,3,2-dioxaborolane in a similar manner to that described for the preparation of trans-5-(4-chloro-7-(4-(4-methylpiperazino)cyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-phenoxybenzonitrile: 1H NMR (DMSO-d6, 400 MHz) δ 8.67 (s, 1H), 8.07(s, 1H), 7.58 (d, 1H), 7.41(m, 3H), 7.22(m, 1H), 7.16(m, 1H), 7.04(d, 2H), 4.70(m, 1H), 2.2-2.6 (m, 9H), 2.16(s, 3H), 1.94-2.03(m, 6H), 1.48(m, 2H); MS MH+520.3; RP-HPLC (Hypersil HS, 5 μm, 100 A 4.6×250 mm; 25%-100% acetonitrile—0.05 M ammonium acetate over 10 min, 1 ml/min) tr 9.45 min.
後処理
- customtr 9.45 min.
出典と根拠
- ORDレコード
- ord-5225ef6536224bf48b1900a5b93b61ef
- 出典データセット
- uspto-grants-2004_03
- 特許番号
- US06713474B2
関連ノート
読み込み中…